Genentech to present ophthalmology data at ARVO 2026
- ARVO Annual Meeting May 3-7 in Denver: Genentech to present more than 45 abstracts, including 20 oral presentations across five retinal conditions.
- VOYAGER (NCT05476926) real-world OCT analysis using a deep-learning algorithm shows six months of faricimab (Vabysmo) reduced retinal fluid in treatment-naïve and previously treated wet AMD and DME patients.
- Susvimo (ranibizumab implant) presentations include Pagoda and Belvedere data and model-based pharmacokinetic simulations assessing sustained delivery and reduced injection burden.
- Vamikibart, an investigational intravitreal IL-6 inhibitor, reports early efficacy/tolerability (DOVETAIL, ALLUVIUM, BARDENAS) and has Phase III studies MEERKAT and SANDCAT underway.
ARVO presentations
Genentech will present more than 45 abstracts, including 20 oral presentations, at the ARVO Annual Meeting (May 3–7, Denver), covering five retinal conditions: geographic atrophy, retinal vein occlusion, uveitic macular edema, diabetic macular edema and neovascular AMD.
Vabysmo real-world VOYAGER data
VOYAGER (NCT05476926) used a deep-learning algorithm to analyze real-world OCT images and found six months of faricimab (Vabysmo) treatment reduced retinal fluid and improved retinal anatomy in both treatment‑naive and previously treated patients with wet AMD and DME; additional analyses explore Vabysmo in RVO and anatomical comparisons versus aflibercept.
Susvimo data on sustained delivery
Presentations include Pagoda and Belvedere trial results and model-based pharmacokinetic simulations for the Port Delivery System with ranibizumab (Susvimo), reporting sustained disease control, comparisons of retinal fluid/thickness/leakage in bilateral DME, and year‑2 patient preference findings versus intravitreal injections.
Vamikibart and pipeline updates
Vamikibart, an investigational intravitreal IL‑6 inhibitor, showed rapid vision improvements and resolution of macular edema with no treatment‑related serious adverse events in Phase I DOVETAIL; first results from Phase II ALLUVIUM and BARDENAS will be presented, and Phase III MEERKAT and SANDCAT are ongoing.
Source: Genentech